Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: A cost-effectiveness analysis

Therapeutic Drug Monitoring

Volumn 21, Issue 1, 1999, Pages 63-73

  Van Lent Evers, Nicolette A E M ^a,d   Mathôt, Ron A A ^a   Geus, William P ^b   Van Hout, Ben A ^c   Vinks, Alexander A T M M ^a,e  

^a Hague Central Hospital Pharmacy   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d Department of Clinical Pharmacy   (Netherlands)

^e Central Hospital Pharmacy   (Netherlands)

Author keywords

Aminoglycosides; Clinical outcome; Cost effectiveness; Gentamicin; Therapeutic drug monitoring

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFAMANDOLE; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; CLINDAMYCIN; ERYTHROMYCIN; FLUCLOXACILLIN; GENTAMICIN; PENICILLIN G;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG MONITORING; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROTOXICITY; PRIORITY JOURNAL;

AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; DRUG MONITORING; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LENGTH OF STAY; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES;

EID: 0033024908     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199902000-00010     Document Type: Article

References (35)

1. Begg EJ, Barclay ML. Aminoglycosides-50 years on. Br J Clin Pharmacol 1995;39:597-603.
2. Janknegt R, Wijnands WJA, Caprasse M, et al. Antimicrobial drug use in hospitals in the Netherlands, Germany and Belgium. Eur J Clin Microbiol Infect Dis 1993;12:832-8.
3. De Broe ME, Giuliano RA, Verpooten GA. Choice of drug and dosage regimen. Two important risk factors for aminoglycoside nephrotoxicity. Am J Med 1986;115-8.
4. Verpooten GA, Giuliano RA, Verbist L, et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989;45:22-7.
5. Zaske DE, Cipolle RJ, Rotschafer JC, et al. Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations. Antimicrob Agents Chemother 1982;21:407-11.
6. Zaske DE, Irvine P, Strand LM, et al. Wide interpatient variations in gentamicin dose requirements for geriatric patients. JAMA 1982; 248:3122-6.
7. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteriemia. J Infect Dis 1984;149:443-8.
8. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984b; 77:657-62.
9. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: Importance of ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155:93-9.
10. Dahlgren JG, Anderson FT, Hewitt WI. Gentamicin blood levels: A guide to nephrotoxicity. Antimicrob Agents Chemother 1975;8: 58-62.
11. Destache CJ, Meyer SK, Bittner MJ, et al. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides. Ther Drug Monit 1990;12:419-26.
12. Destache CJ, Meyer SK, Rowley KM. Does accepting pharmacokinetic recommendations impact hospitalization? A cost-benefit analysis. Ther Drug Monit 1990;12:427-33.
13. Bertino JS, Rodvold KA, Destache CJ. Cost considerations in therapeutic drug monitoring of aminoglycosides. Clin Pharmacokinet 1994;26:71-81.
14. Crist KD, Nahata MC, Ety J. Positive impact of a therapeutic drug-monitoring program on total aminoglycoside dose and cost of hospitalization. Ther Drug Monit 1987;9:306-10.
15. Bootman JL, Zaske DF, Wertheimer AI, Rowland C. Individualized gentamicin dosage regimens in burn patients with Gram-negative septicemia: A cost-benefit analysis. J Pharm Sci 1979; 68:267-72.
16. Kimelblatt BJ, Bradbury K, Chodoff L, et al. Cost-benefit analysis of an aminoglycoside monitoring service. Am J Hosp Pharm 1986; 43:1205-9.
17. Vinks AATMM, Touw DJ, Fockens E. The impact of an active laboratory approach on therapeutic drug monitoring. In: Sunshine I, ed. Recent developments in therapeutic drug monitoring and clinical toxicology. New York: Dekker, 1992:19-26.
18. Greuell SE, Van't Wout JW, Bijlmer HA, et al. Investigation and evaluation of antibiotics use in a general hospital. Ziekenhuisfarmacie 1993;9:135-9.
19. Jelliffe RW, Schumitzky A, Bayard D, et al. Model-based, goal-oriented individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design. Bayesian feedback and individualised target goals. Clin Pharmacokinet 1998;34:57-77.
20. Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: Gentamicin in burn patients. J Pharmacokin Biopharm 1976;4:183-95.
21. Touw DJ, Vinks AATMM, Heijerman HGM, et al. Validation of tobramycin monitoring in adolescent and adult patients with cystic fibrosis. Ther Drug Monit 1993;15:52-9.
22. Proost JH, Meijer DKF. MW/PHARM, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992;22:155-63.
23. Jelliffe RW, Gomis P, Schumitzky A. A population model of gentamicin made with a new nonparametric EM algorithm. Clin Pharmacol Ther 1991;49:153.
24. Jelliffe RW, Schumitzky A, Van Guilder M, et al. Individualizing dosage regimens: roles of population pharmacokinetics and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit 1993;15:380-93.
25. Jelliffe RW, Schumitzky A, Van Guilder M. Users manual for version 10.0 of the USC*PACK collection of PC programs. Los Angeles: Laboratory of Applied Pharmacokinetics, University of Southern California School of Medicine, 1994.
26. Evers NAEM, Vinks AATMM. Development of gentamicin population models for ICU and nonICU patients using a nonparametric algorithm (NPEM). Ther Drug Monit 1995;4:424.
27. Rutten FFH, Van Ineveld BM, Van Ommen R, et al. Cost calculations in health care research. Guidelines for clinical practice. Rijswijk, The Netherlands: van Arkel, 1993.
28. Van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and C/E ratios alongside a clinical trial. Health Econ 1994;3:309-19.
29. Black WE. The CE plane: A graphical presentation of cost-effectiveness. Medical Decision Making 1990;10:212-4.
30. Ensom MHH, Davis GA, Cropp CD, et al. Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes? Clin Pharmacokinet 1998;34:265-79.
31. Burton ME, Ash CL, Hill DP, et al. A controlled trial of the cost benefit of computerized Bayesian aminoglycoside administration. Clin Pharmacol Ther 1991;49:685-94.
32. Van Hout BA, Bowman L, Zelinger DJ, et al. Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergoing percutaneous trans luminal coronary angioplasty in the EPIC study. Am Heart J 1998;135:1-9.
33. Eisenberg JM, Koffer H, Glick HA, et al. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med 1987;107:900-9.
34. Brushwood DB. Government liable for failure to monitor a patient's serum gentamicin concentration in an army hospital. Am J Hosp Pharm 1992;49:1748-50.
35. Kashuba ADM, Nafzinger AN, Drusano GL, et al. Early optimization reduces time to therapeutic response in Gram-negative pneumonia. In: Proceedings 36th interscience conference on antimicrobial agents and chemotherapy, New Orleans, LA, 1996. Washington, DC: American Society of Microbiology.